Monday, June 24, 2013

Xtandi approved in Europe for Advanced prostate cancer patients having failed prior docetaxel therapy

Enzalutamide (Xtandi) has been authorised in European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.  Enzalutamide is a novel, once-daily, oral androgen receptor signalling inhibitor.33 It inhibits multiple steps in the androgen receptor (AR) signalling pathway, which has been shown to decrease cancer cell growth and induce cancer cell death (apoptosis)
Upon receiving marketing authorisation in Europe, Astellas will provide Medivation with a $15 million milestone payment, as reflected in Astellas’ current fiscal year (from 1st April 2013 to 31st March 2014) financial forecast


Enter your email address:


Delivered by FeedBurner